Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.49
ACET's Cash to Debt is ranked lower than
76% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. ACET: 0.49 )
Ranked among companies with meaningful Cash to Debt only.
ACET' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 5.64 Max: 83.22
Current: 0.49
0.3
83.22
Equity to Asset 0.55
ACET's Equity to Asset is ranked lower than
62% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ACET: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
ACET' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.67 Max: 0.77
Current: 0.55
0.5
0.77
Interest Coverage 12.40
ACET's Interest Coverage is ranked lower than
72% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. ACET: 12.40 )
Ranked among companies with meaningful Interest Coverage only.
ACET' s Interest Coverage Range Over the Past 10 Years
Min: 9.66  Med: 31.06 Max: 147.43
Current: 12.4
9.66
147.43
F-Score: 6
Z-Score: 3.98
M-Score: -2.41
WACC vs ROIC
10.39%
12.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.95
ACET's Operating margin (%) is ranked higher than
58% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. ACET: 11.95 )
Ranked among companies with meaningful Operating margin (%) only.
ACET' s Operating margin (%) Range Over the Past 10 Years
Min: 2.72  Med: 5.26 Max: 10.3
Current: 11.95
2.72
10.3
Net-margin (%) 7.11
ACET's Net-margin (%) is ranked higher than
52% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. ACET: 7.11 )
Ranked among companies with meaningful Net-margin (%) only.
ACET' s Net-margin (%) Range Over the Past 10 Years
Min: 1.9  Med: 3.51 Max: 6.12
Current: 7.11
1.9
6.12
ROE (%) 15.42
ACET's ROE (%) is ranked higher than
73% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. ACET: 15.42 )
Ranked among companies with meaningful ROE (%) only.
ACET' s ROE (%) Range Over the Past 10 Years
Min: 4.68  Med: 9.34 Max: 13.73
Current: 15.42
4.68
13.73
ROA (%) 8.03
ACET's ROA (%) is ranked higher than
69% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. ACET: 8.03 )
Ranked among companies with meaningful ROA (%) only.
ACET' s ROA (%) Range Over the Past 10 Years
Min: 3.01  Med: 5.80 Max: 7.33
Current: 8.03
3.01
7.33
ROC (Joel Greenblatt) (%) 41.84
ACET's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. ACET: 41.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACET' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 12.2  Med: 22.79 Max: 38.21
Current: 41.84
12.2
38.21
Revenue Growth (3Y)(%) 4.10
ACET's Revenue Growth (3Y)(%) is ranked lower than
56% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ACET: 4.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACET' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0.9  Med: 4.20 Max: 15
Current: 4.1
0.9
15
EBITDA Growth (3Y)(%) 23.00
ACET's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. ACET: 23.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACET' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -11  Med: 7.30 Max: 45.1
Current: 23
-11
45.1
EPS Growth (3Y)(%) 21.80
ACET's EPS Growth (3Y)(%) is ranked higher than
73% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. ACET: 21.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACET' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.6  Med: 6.60 Max: 46
Current: 21.8
-17.6
46
» ACET's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ACET Guru Trades in Q1 2015

Chuck Royce 1,905,066 sh (-9.76%)
Jim Simons 362,500 sh (-11.30%)
» More
Q2 2015

ACET Guru Trades in Q2 2015

Jim Simons 310,200 sh (-14.43%)
Chuck Royce 1,603,952 sh (-15.81%)
» More
Q3 2015

ACET Guru Trades in Q3 2015

Ken Fisher 151,870 sh (New)
Jim Simons 383,300 sh (+23.57%)
Chuck Royce 859,813 sh (-46.39%)
» More
Q4 2015

ACET Guru Trades in Q4 2015

Ken Fisher 185,382 sh (+22.07%)
Jim Simons 297,900 sh (-22.28%)
Chuck Royce 307,790 sh (-64.20%)
» More
» Details

Insider Trades

Latest Guru Trades with ACET

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.74
ACET's P/E(ttm) is ranked higher than
79% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.27 vs. ACET: 14.74 )
Ranked among companies with meaningful P/E(ttm) only.
ACET' s P/E(ttm) Range Over the Past 10 Years
Min: 8.5  Med: 19.59 Max: 78.71
Current: 14.74
8.5
78.71
Forward P/E 19.72
ACET's Forward P/E is ranked lower than
62% of the 412 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.50 vs. ACET: 19.72 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 14.62
ACET's PE(NRI) is ranked higher than
81% of the 554 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.00 vs. ACET: 14.62 )
Ranked among companies with meaningful PE(NRI) only.
ACET' s PE(NRI) Range Over the Past 10 Years
Min: 8.5  Med: 19.56 Max: 91.83
Current: 14.62
8.5
91.83
P/B 2.04
ACET's P/B is ranked higher than
60% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ACET: 2.04 )
Ranked among companies with meaningful P/B only.
ACET' s P/B Range Over the Past 10 Years
Min: 0.83  Med: 1.53 Max: 3.37
Current: 2.04
0.83
3.37
P/S 1.05
ACET's P/S is ranked higher than
79% of the 935 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. ACET: 1.05 )
Ranked among companies with meaningful P/S only.
ACET' s P/S Range Over the Past 10 Years
Min: 0.31  Med: 0.58 Max: 1.62
Current: 1.05
0.31
1.62
PFCF 44.16
ACET's PFCF is ranked lower than
67% of the 464 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.12 vs. ACET: 44.16 )
Ranked among companies with meaningful PFCF only.
ACET' s PFCF Range Over the Past 10 Years
Min: 7.6  Med: 22.14 Max: 543
Current: 44.16
7.6
543
POCF 23.95
ACET's POCF is ranked lower than
55% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.66 vs. ACET: 23.95 )
Ranked among companies with meaningful POCF only.
ACET' s POCF Range Over the Past 10 Years
Min: 6.09  Med: 21.35 Max: 268
Current: 23.95
6.09
268
EV-to-EBIT 10.70
ACET's EV-to-EBIT is ranked higher than
77% of the 804 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.88 vs. ACET: 10.70 )
Ranked among companies with meaningful EV-to-EBIT only.
ACET' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.2  Med: 11.20 Max: 45.7
Current: 10.7
4.2
45.7
EV-to-EBITDA 9.10
ACET's EV-to-EBITDA is ranked higher than
75% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.62 vs. ACET: 9.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACET' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 9.80 Max: 22.2
Current: 9.1
4
22.2
PEG 0.44
ACET's PEG is ranked higher than
92% of the 276 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. ACET: 0.44 )
Ranked among companies with meaningful PEG only.
ACET' s PEG Range Over the Past 10 Years
Min: 0.35  Med: 1.33 Max: 372.29
Current: 0.44
0.35
372.29
Shiller P/E 30.13
ACET's Shiller P/E is ranked higher than
63% of the 175 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.02 vs. ACET: 30.13 )
Ranked among companies with meaningful Shiller P/E only.
ACET' s Shiller P/E Range Over the Past 10 Years
Min: 11.39  Med: 20.33 Max: 46.78
Current: 30.13
11.39
46.78
Current Ratio 3.21
ACET's Current Ratio is ranked higher than
62% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. ACET: 3.21 )
Ranked among companies with meaningful Current Ratio only.
ACET' s Current Ratio Range Over the Past 10 Years
Min: 2.12  Med: 3.02 Max: 4
Current: 3.21
2.12
4
Quick Ratio 2.18
ACET's Quick Ratio is ranked higher than
59% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. ACET: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
ACET' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.89 Max: 2.71
Current: 2.18
1.21
2.71
Days Inventory 85.92
ACET's Days Inventory is ranked higher than
69% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. ACET: 85.92 )
Ranked among companies with meaningful Days Inventory only.
ACET' s Days Inventory Range Over the Past 10 Years
Min: 73.32  Med: 81.16 Max: 87.05
Current: 85.92
73.32
87.05
Days Sales Outstanding 99.63
ACET's Days Sales Outstanding is ranked lower than
73% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. ACET: 99.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACET' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.39  Med: 70.94 Max: 107.79
Current: 99.63
61.39
107.79
Days Payable 51.22
ACET's Days Payable is ranked lower than
74% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. ACET: 51.22 )
Ranked among companies with meaningful Days Payable only.
ACET' s Days Payable Range Over the Past 10 Years
Min: 34.34  Med: 45.41 Max: 54.3
Current: 51.22
34.34
54.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.21
ACET's Dividend Yield is ranked lower than
59% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. ACET: 1.21 )
Ranked among companies with meaningful Dividend Yield only.
ACET' s Dividend Yield Range Over the Past 10 Years
Min: 0.79  Med: 2.15 Max: 4.01
Current: 1.21
0.79
4.01
Dividend Payout 0.18
ACET's Dividend Payout is ranked higher than
85% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. ACET: 0.18 )
Ranked among companies with meaningful Dividend Payout only.
ACET' s Dividend Payout Range Over the Past 10 Years
Min: 0.13  Med: 0.52 Max: 2.5
Current: 0.18
0.13
2.5
Dividend Growth (3y) 6.30
ACET's Dividend Growth (3y) is ranked higher than
50% of the 280 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. ACET: 6.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ACET' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -1.5  Med: 6.30 Max: 22.6
Current: 6.3
-1.5
22.6
Forward Dividend Yield 1.21
ACET's Forward Dividend Yield is ranked lower than
63% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ACET: 1.21 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.47
ACET's Yield on cost (5-Year) is ranked lower than
57% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.86 vs. ACET: 1.47 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ACET' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.98  Med: 2.68 Max: 5
Current: 1.47
0.98
5
3-Year Average Share Buyback Ratio -2.90
ACET's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.90 vs. ACET: -2.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACET' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.7  Med: -1.20 Max: 5.6
Current: -2.9
-3.7
5.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 6.50
ACET's Price/Net Current Asset Value is ranked higher than
51% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.50 vs. ACET: 6.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACET' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.99  Med: 1.88 Max: 12.62
Current: 6.5
0.99
12.62
Price/Tangible Book 4.37
ACET's Price/Tangible Book is ranked lower than
57% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. ACET: 4.37 )
Ranked among companies with meaningful Price/Tangible Book only.
ACET' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.91  Med: 1.58 Max: 7.26
Current: 4.37
0.91
7.26
Price/Projected FCF 1.56
ACET's Price/Projected FCF is ranked higher than
65% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.16 vs. ACET: 1.56 )
Ranked among companies with meaningful Price/Projected FCF only.
ACET' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.48  Med: 1.01 Max: 2.75
Current: 1.56
0.48
2.75
Price/Median PS Value 1.81
ACET's Price/Median PS Value is ranked lower than
77% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.12 vs. ACET: 1.81 )
Ranked among companies with meaningful Price/Median PS Value only.
ACET' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.41  Med: 0.93 Max: 2.52
Current: 1.81
0.41
2.52
Price/Peter Lynch Fair Value 0.63
ACET's Price/Peter Lynch Fair Value is ranked higher than
85% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. ACET: 0.63 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ACET' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.4  Med: 1.36 Max: 6.19
Current: 0.63
0.4
6.19
Price/Graham Number 1.68
ACET's Price/Graham Number is ranked higher than
63% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. ACET: 1.68 )
Ranked among companies with meaningful Price/Graham Number only.
ACET' s Price/Graham Number Range Over the Past 10 Years
Min: 0.6  Med: 1.13 Max: 3
Current: 1.68
0.6
3
Earnings Yield (Greenblatt) (%) 9.38
ACET's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ACET: 9.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACET' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.2  Med: 8.90 Max: 23.6
Current: 9.38
2.2
23.6
Forward Rate of Return (Yacktman) (%) 25.83
ACET's Forward Rate of Return (Yacktman) (%) is ranked higher than
86% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.77 vs. ACET: 25.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ACET' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.5  Med: 12.40 Max: 49.1
Current: 25.83
-1.5
49.1

More Statistics

Revenue(Mil) $558
EPS $ 1.35
Beta1.35
Short Percentage of Float8.06%
52-Week Range $18.03 - 32.20
Shares Outstanding(Mil)29.55

Analyst Estimate

Jun16
Revenue(Mil)
EPS($) 1.23
EPS without NRI($) 1.23

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NEU, SCL, VAL, POL, CYT » details
Traded in other countries:AZJ.Germany,
Aceto Corp is engaged in the marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals. Its operations are organized into three segments - Human Health, Pharmaceutical Ingredients and Performance Chemicals. The Human Health segment supply's raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. This segment markets and distributes its generic prescription and over the counter pharmaceutical products to wholesalers; chain drug stores; distributors; mass market merchandisers; and others. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals, such as antioxidants, photo initiators, catalysts, curatives, brighteners, and adhesion promoters, which make plastics, surface coatings, textiles, fuels, and lubricants; diazos and couplers used in microfilms and blueprints, as well as in the photo tooling of printed circuit boards; and organic intermediates and colorants. Its raw materials are also used in electronic parts and binders. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitor for potatoes. The Company serves various companies, including small trading and fortune 500 companies in the industrial chemical, agricultural, and human health and pharmaceutical market.
» More Articles for ACET

Headlines

Articles On GuruFocus.com
5 Biggest Dividend Hikes Of The Past Week Aug 31 2013 
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 
Aceto Corp. Reports Operating Results (10-Q) Feb 04 2011 
Aceto Corp. Reports Operating Results (10-Q) Nov 05 2010 
Aceto Corp. Reports Operating Results (10-Q) May 07 2010 
Aceto Corp. Reports Operating Results (10-Q) Feb 05 2010 
Aceto Corp. Reports Operating Results (10-Q) Nov 06 2009 
Aceto Corp. Reports Operating Results (10-Q) May 08 2009 
Aceto Corp. Reports Operating Results (10-Q) Feb 06 2009 

More From Other Websites
ACETO CORP Financials Feb 11 2016
Edited Transcript of ACET earnings conference call or presentation 5-Feb-16 2:00pm GMT Feb 08 2016
Aceto Corp. Earnings Analysis: Q2, 2016 By the Numbers Feb 08 2016
Aceto Corp Earnings Call scheduled for 9:00 am ET today Feb 05 2016
ACETO CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 05 2016
Aceto posts 2Q profit Feb 04 2016
Aceto posts 2Q profit Feb 04 2016
ACETO Reports Fiscal 2016 Second Quarter Results Feb 04 2016
ACETO Board of Directors Declares Quarterly Cash Dividend Feb 04 2016
Q2 2015/2016 Aceto Corp Earnings Release - After Market Close Feb 04 2016
ACETO Corporation Schedules Second Quarter & Fiscal 2016 Financial Results News Release and... Jan 27 2016
ACETO Corporation Schedules Second Quarter & Fiscal 2016 Financial Results News Release and... Jan 27 2016
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Zolmitriptan Tablets Jan 25 2016
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Zolmitriptan Tablets Jan 25 2016
Forget Powerball, these stocks will actually make money: ... Jan 13 2016
Aceto Corp. Earnings Analysis: Q1, 2016 By the Numbers Dec 16 2015
ACETO CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 16 2015
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Olopatadine Hydrochloride Ophthalmic Solution Dec 07 2015
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Olopatadine Hydrochloride Ophthalmic Solution Dec 07 2015
ACETO Board of Directors Declares Quarterly Cash Dividend Dec 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK